API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

9

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Incyte Corporation

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and So...

Details:

CMS will be responsible for the development and commercialization of INCB54707 (povorcitinib), a selective oral JAK1 inhibitor, which is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma & chronic spontaneous urticaria.

Lead Product(s): Povorcitinib

Therapeutic Area: Dermatology Product Name: INCB054707

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: China Medical System Holdings Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 01, 2024

ASK
US

Upload
your Marketing & Sales content

Incyte Corporation

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Details:

INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for adult patients with prurigo nodularis. A Phase 3 trial is being planned for prurigo nodularis.

Lead Product(s): Povorcitinib

Therapeutic Area: Dermatology Product Name: INCB054707

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2024

ASK
US

Upload
your Marketing & Sales content

Incyte Corporation

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Details:

INCB54707 (povorcitinib) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis. A Phase 3 study in HS is also ongoing.

Lead Product(s): Povorcitinib

Therapeutic Area: Dermatology Product Name: INCB054707

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2023

ASK
US

Upload
your Marketing & Sales content

Incyte Corporation

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

Details:

Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), vitiligo and prurigo nodularis.

Lead Product(s): Povorcitinib

Therapeutic Area: Dermatology Product Name: INCB054707

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2022

ASK
US

Upload
your Marketing & Sales content